 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Foundations of Hereditary Breast and Ovarian Cancer Syndrome

Introduction to Hereditary Breast and Ovarian Cancer Syndrome

Core Genetic Concepts for HBOC

HBOC-Associated Genes and Cancer Risks

BRCA1 and BRCA2: High-Penetrance HBOC Genes

PALB2: A Moderate-to-High Penetrance Breast Cancer Gene

CHEK2 and ATM: Moderate-Penetrance Cancer Susceptibility Genes

Interpreting Gene-Specific Risk in Clinical Context

Clinical Surveillance and Early Detection

Breast Cancer Surveillance for HBOC-Associated Variants

Ovarian Cancer Risk Assessment and Surveillance Limitations

Surveillance for Other HBOC-Associated Cancers

Risk-Reducing Strategies and Surgical Options

Risk-Reducing Approaches Beyond Surgery

Risk-Reducing Mastectomy

Risk-Reducing Salpingo-Oophorectomy and Related Considerations

Counseling, Referrals, and Long-Term Follow-Up

Quiz

Question 1: HBOC-Associated Genes

Question 2: Penetrance

Question 3: Breast Surveillance

Question 4: Ovarian Cancer Screening

Question 5: Risk-Reducing Surgery

Survey and Feedback

Course Feedback Survey

Welcome to the comprehensive course on Hereditary Breast and Ovarian Cancer (HBOC): Genetics, Risk, and Surveillance. Approximately 5-10% of breast and ovarian cancers are hereditary, driven by pathogenic variants in genes such as BRCA1, BRCA2, PALB2, CHEK2, and ATM.

Welcome to the comprehensive course on Hereditary Breast and Ovarian Cancer (HBOC): Genetics, Risk, and Surveillance. Approximately 5-10% of breast and ovarian cancers are hereditary, driven by pathogenic variants in genes such as BRCA1, BRCA2, PALB2, CHEK2, and ATM. Understanding the genetic foundations of these cancers is critical for modern clinical practice, enabling healthcare professionals to identify at-risk individuals, interpret genetic test results, and implement life-saving surveillance and risk-reducing strategies.

This course provides an in-depth exploration of HBOC syndrome, moving from core genetic concepts to advanced clinical applications. You will learn to distinguish between high-penetrance and moderate-penetrance genes, understand the implications of variants of uncertain significance (VUS), and navigate the complexities of gene-specific risk assessment. We will delve into evidence-based surveillance protocols for breast, ovarian, pancreatic, and prostate cancers, highlighting the benefits and limitations of current screening modalities like MRI and transvaginal ultrasounds.

Furthermore, the curriculum covers critical risk-reducing interventions, including non-surgical approaches, risk-reducing mastectomy, and risk-reducing salpingo-oophorectomy (RRSO). By emphasizing a patient-centered approach, shared decision-making, and the importance of genetic counseling, this course equips clinicians, genetic counselors, and oncology specialists with the knowledge needed to deliver individualized, guideline-informed care. Join us to enhance your clinical expertise and improve outcomes for patients and families affected by hereditary cancer syndromes.

Hereditary Breast and Ovarian Cancer: Genetics, Risk, and Surveillance

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Hereditary Breast and Ovarian Cancer (HBOC) syndrome represents a critical area of oncological and genetic medicine, characterized by an inherited predisposition to specific malignancies. Understanding the genetic underpinnings of HBOC is essential for identifying at-risk individuals and implementing effective, life-saving interventions. This course provides a comprehensive examination of the genetic mutations associated with HBOC, moving beyond the well-known BRCA1 and BRCA2 genes to include moderate-to-high penetrance genes such as PALB2, CHEK2, and ATM. By exploring the foundational concepts of germline variants, penetrance, and the clinical significance of variants of uncertain significance (VUS), learners will develop a robust framework for evaluating personal and family history patterns that necessitate genetic referral and specialized care.</p>

<p>Building upon this genetic foundation, the curriculum systematically addresses the clinical management of individuals with elevated cancer risks. Participants will examine evidence-based surveillance protocols for breast, ovarian, pancreatic, and prostate cancers, while critically evaluating the limitations of current screening modalities. Furthermore, the course delves into comprehensive risk-reducing strategies, encompassing both non-surgical approaches and surgical options such as risk-reducing mastectomy and risk-reducing salpingo-oophorectomy (RRSO). Through a patient-centered lens, the material emphasizes the importance of individualized risk assessment, shared decision-making, genetic counseling, and cascade testing, ensuring that clinical recommendations are meticulously tailored to each patient's unique genetic profile, family history, and personal values.</p>
        </div>
    </div>
</div>
